METHOD OF TREATMENT OF NEUROLOGICAL INJURY OR CANCER BY ADMINISTRATION OF DICHLOROACETATE

• US 20080221211A1
• Filed: 02/01/2008
• Published: 09/11/2008
• Est. Priority Date: 02/02/2007
• Status: Abandoned Application

• Current Assignee: Jackson Streeter
• Original Assignee: Jackson Streeter
• Inventors: Streeter, Jackson
• Application Number:
  US12/024,276
• Publication Number:
  US 20080221211A1
• Time in Patent Office: Days
• US Class Current: 514/557
• CPC Class Codes: A61K 31/19 Carboxylic acids, e.g. valproic acid salicylic acid A61K31/60
• CPC Class Codes: A61N 2005/007 for cooling the patient
• CPC Class Codes: A61N 2005/0647 the applicator adapted to be worn on the head
• CPC Class Codes: A61N 5/0613 Apparatus adapted for a specific treatment
• CPC Class Codes: A61N 5/0617 Hair treatment
• CPC Class Codes: A61N 5/067 using laser light

Abstract

A method for treating neurological injury or cancer in a patient includes administration of a therapeutically-effective amount of dichloroacetic acid (DCA), a therapeutically-effective amount of electromagnetic radiation, or both to the patient.

Claims

1. A method of providing treatment to a patient with a neurological injury, the method comprising administering a therapeutically-effective amount of dichloroacetic acid (DCA) to the patient.

2. The method of claim 1, wherein the therapeutically-effective amount of DCA is administered orally.

3. The method of claim 1, wherein the therapeutically-effective amount of DCA is administered intravenously.

4. The method of claim 1, wherein the therapeutically-effective amount of DCA is in a range between about 1.0 mg/kg/day and about 25 mg/kg/day.

5. The method of claim 1, wherein the neurological injury comprises traumatic brain injury.

6. The method of claim 1, wherein the neurological injury comprises ischemic stroke.

7. The method of claim 1, the method further comprising applying a therapeutically-effective amount of electromagnetic radiation to the brain.

8. The method of claim 7, wherein the therapeutically-effective amount of electromagnetic radiation is applied within 5 days of the onset of neurological injury.

9. The method of claim 7, wherein the therapeutically-effective amount of electromagnetic radiation has a wavelength within a range between about 630 nanometers and about 1064 nanometers.

10. The method of claim 7, wherein the therapeutically-effective amount of electromagnetic radiation comprises a power density of at least 0.01 mW/cm².

11. The method of claim 7, wherein applying the therapeutically-effective amount of electromagnetic radiation is performed concurrently with administering the therapeutically-effective amount of DCA.

12. The method of claim 7, wherein applying the therapeutically-effective amount of electromagnetic radiation is performed non-concurrently with administering the therapeutically-effective amount of DCA.

13. The method of claim 12, wherein applying the therapeutically-effective amount of electromagnetic radiation is performed before administering the therapeutically-effective amount of DCA.

14. A method of providing treatment to a cancer patient, the method comprising applying a therapeutically-effective amount of electromagnetic radiation to the patient.

15. The method of claim 14, wherein the electromagnetic radiation has a wavelength within a range between about 630 nanometers and about 1064 nanometers.

16. The method of claim 14, wherein the therapeutically-effective amount of electromagnetic radiation comprises a power density of at least 0.01 mW/cm².

17. A method of providing treatment to a cancer patient, the method comprising administering a therapeutically-effective amount of dichloroacetic acid (DCA) and applying a therapeutically-effective amount of electromagnetic radiation to the patient.

18. The method of claim 17, wherein the therapeutically-effective amount of DCA is administered orally.

19. The method of claim 17, wherein the therapeutically-effective amount of DCA is administered intravenously.

20. The method of claim 17, wherein the therapeutically-effective amount of DCA is in a range between about 1.0 mg/kg/day and about 25 mg/kg/day.

21. The method of claim 17, wherein the electromagnetic radiation has a wavelength within a range between about 630 nanometers and about 1064 nanometers.

22. The method of claim 17, wherein the therapeutically-effective amount of electromagnetic radiation comprises a power density of at least 0.01 mW/cm².

23. The method of claim 17, wherein applying the therapeutically-effective amount of electromagnetic radiation is performed concurrently with administering the therapeutically-effective amount of DCA.

24. The method of claim 17, wherein applying the therapeutically-effective amount of electromagnetic radiation is performed non-concurrently with administering the therapeutically-effective amount of DCA.

25. The method of claim 24, wherein applying the therapeutically-effective amount of electromagnetic radiation is performed before administering the therapeutically-effective amount of DCA.